Analysis Date: 2025-12-11T16:03:28.258020 Trading Period: 2025-12-08 to 2025-12-19
Company: BioCryst Pharmaceuticals, Inc. Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic Current Price: $7.57 Market Cap: $1,592,759,552 Beta: 0.91 Avg Volume: 4,971,650 Website: https://www.biocryst.com
Description: BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phas...
Action: STRONG AVOID Confidence: 20.0/100 Position Size: 0.0% of portfolio
Rationale: Unfavorable conditions (composite: 29.8/100, risk: EXTREME, red flags: 5).
Key Risks:
Passed Filters: ✓ Yes Notes: Passed all screening filters
Composite Score: 3.20/5.0 Percentile Rank: 50%
Factor Scores:
Setup Score: 1/8 Setup Notes: In uptrend
Price Levels:
Momentum & Volume:
Risk Level: EXTREME Confidence: 10.0/100 Total Red Flags: 5 Earnings Risk: No
Critical Issues:
Market Red Flags:
Stock-Specific Red Flags:
This report is generated by PM automated research system. Always perform your own due diligence before trading.